ANTX vs EBS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ANTX Captures Institutional Edge (3โ1 Pillars ยท 4โ6 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AN2 Therapeutics, Inc. Common Stock (ANTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while EBS counters with relative strength in Valuation. Fundamentally, ANTX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus EBS at 19.3x Forward P/E and 5.8% operating margin (-52.4% YoY). In options structure, ANTX sits in CONSOLIDATION (22nd %ile IV; Dealer Gamma Walls on Pro) against EBS sits in BREAKDOWN (5th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ANTX | EBS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $190.1M | $282.8M | Larger Scale | EBS |
| Trailing P/E Ratio Valuation | N/M | 19.3x | Lower Multiple | EBS |
| Forward P/E Ratio Valuation | N/M | 19.3x | Lower Multiple | EBS |
| Revenue Growth (YoY) Growth | +0.0% | -52.4% | Higher Growth | ANTX |
| Operating Margin (TTM) Profitability | 0.0% | 5.8% | Higher Margin | EBS |
| Net Profit Margin Profitability | 0.0% | -40.2% | Higher Margin | ANTX |
| Return on Equity (ROE) Capital Efficiency | -51.3% | -58.2% | Higher ROE | ANTX |
| 52-Week Range Position Momentum | 68% ($1โ$7) | 8% ($4โ$14) | Stronger Trend | ANTX |
| Beta / 30D Volatility Risk Regime | 0.75ฮฒ ยท 98% Vol | 0.90ฮฒ ยท 54% Vol | Lower Realized Risk | EBS |
| Unified Institutional Score Composite Signal | 37.2 / 100 (SELL) | 42.6 / 100 (HOLD) | Higher Composite | EBS |